Verisante expands its sales and marketing team
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has hired Jason Mangler as director of sales to guide the company’s worldwide sales and marketing strategy and also hired Kim Ellis as its sales...
View ArticleClik here to view.
Verisante recognizes skin cancer awareness month
May is skin cancer awareness month and Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) is reminding the public to wear sunscreen and get screened for skin cancer. Skin cancer is the most common form of...
View ArticleClik here to view.
Verisante completes Core prototype
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has completed the development of the Core series commercial prototype to aid in the detection of lung cancer. The Core system, which is based on the same...
View ArticleClik here to view.
Verisante receives F&S technology innovation award
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has received the Frost & Sullivan 2014 North American Technology Innovation Leadership of the Year Award for In Vivo Cancer Detection for its skin...
View ArticleClik here to view.
Verisante in preliminary license agreement for upper GI cancer detection...
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has signed a letter of intent with Astoria Capital SA, to sublicense and, in turn, finance the development and commercialization of Verisante’s cancer...
View ArticleClik here to view.
Verisante displays Aura at BC Cancer Foundation
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) is partnering with the BC Cancer Foundation to showcase Verisante Aura, a device for the rapid detection of skin cancer. Aura “We are very appreciative of...
View ArticleClik here to view.
Verisante in sales pact for Core device in China
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has closed a $300,000 private placement in conjunction with signing a letter of intent with a strategic partner for the exclusive marketing and sales...
View ArticleClik here to view.
Verisante adds Drs. Beer and Werschler to its CAB
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has appointed Dr. Kenneth Beer and Dr. Wm. Philip Werschler to the company’s clinical advisory board. “Both Dr. Beer and Dr. Werschler have extensive...
View ArticleClik here to view.
Verisante begins FDA approval process for Aura
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has initiated communications with the FDA for the approval of Aura, a device for the detection of skin cancer. “Verisante has now submitted documents to...
View ArticleClik here to view.
Verisante closes private placement
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has closed a private placement of 2.5 million common shares at a price of 14 cents each for gross proceeds of $350,000. The private placement was made with...
View ArticleClik here to view.
Verisante appoints Dr. Branko Palcic to its board
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has appointed Dr. Branko Palcic to its board, effective immediately, replacing Joe Biegel, who has resigned. In a statement, president and CEO, Thomas...
View ArticleVerisante to seek FDA approval of Aura skin cancer device
In addition to ramping up distribution of its Aura non-invasive skin cancer detection device this year, Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) is preparing the process to seek FDA approval of...
View Article
